GBGorav Batra

Gorav Batra

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Gorav Batra has a total of 956 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Diabetes status, fasting glucose and HbA1c, and outcomes after myocardial infarction: a retrospective registry-based Swedish cohort study

    by Azzum Haider, Emil Hagström, Divan Ishak, Nermin Hadziosmanovic, Anna Norhammar, Matthijs Velders, Gorav Batra

    Objectives: This study aimed to assess cardiovascular (CV) risk across the full spectrum of dysglycaemia levels following myocardial infarction (MI). Design: Retrospective registry-based cohort study. Setting: All patients with MI in Sweden registered in the cardiac rehabilitation registry within the Swedish Web-system for Enhancement and Development of Evidence-based care in Heart disease Evaluated According to Recommended Therapies (SWEDEHEART) between 2006 and 2017. Participants: In total, 47 558 patients over the age of 18 attending cardiac rehabilitation post-MI, with available information on glycaemic levels. Primary and secondary outcome measures: The primary outcome was major adverse CV events (MACE), a composite of all-cause mortality, MI and ischaemic stroke until the end of follow-up (30 June 2018). Secondary outcomes included all the components of MACE, CV mortality and hospitalisation for heart failure. Results: Pre-diabetes and possible diabetes were present in 20.6%, new-onset diabetes in 3.2% and known diabetes in 21.1%. During a median follow-up of 4.7 years, 9321 patients experienced MACE. A stepwise increase across glycaemic categories was observed, with HRs of 1.07 (95% CI 1.00 to 1.14) for pre-diabetes, 1.22 (95% CI 1.11 to 1.34) for possible diabetes, 1.22 (95% CI 1.08 to 1.37) for new-onset diabetes and 1.73 (95% CI 1.64 to 1.82) for known diabetes, compared with normoglycaemia. A near-linear association between fasting glucose and outcomes was observed across all patients, while glycated haemoglobin appears predictive mainly in those with established diabetes. Conclusions: Glycaemic disturbances early after MI, including hyperglycaemia below the diagnostic threshold for diabetes, are associated with a progressively higher risk of adverse outcomes. Beyond routine screening, these findings support close follow-up of at-risk patients, irrespective of diabetes status.

  • Open Access

    Implementation of novel antithrombotic treatment strategies and outcome improvements in patients with myocardial infarction and atrial fibrillation over 20 years: a nationwide cohort study

    by Christian Losciale, Lars Lindhagen, Lars Wallentin, Tomas Jernberg, Joakim Alfredsson, Jonas Oldgren, Gorav Batra

    Aims: Patients with acute myocardial infarction (MI) and atrial fibrillation (AF) present challenges in antithrombotic treatment. Effects of newer treatment strategies on outcomes remain uncertain. We assessed implementation of antithrombotic treatment and occurrence of cardiovascular (CV) events and major bleeding in patients with MI and AF. Methods and results: Nationwide data from SWEDEHEART and national health registries were used to identify 71 513 survivors of an acute MI with AF between 2000 and 2021. Changes in antithrombotic therapies over time in 2-year cohorts were analysed, and associations with 1-year outcomes were assessed. The outcomes were ischaemic stroke or systemic embolism, MI, major bleeding, CV mortality and all-cause mortality. Logistic regression was used to standardize for changes in patient characteristics and treatment over time. Oral anticoagulant use increased from 21% in 2000–2001 to 75% in 2020–2021, largely due to adoption of direct oral anticoagulants (DOACs) after the first DOAC approval in 2011, most often combined with a single antiplatelet. Over time, particularly in the last decade, 1-year risk of ischaemic stroke or systemic embolism declined from 6.0% to 2.1%, and CV mortality decreased from 19.8% to 10.5%. Major bleeding increased from 3.9% to 7.6% in 2014–2015, then declined to 6.4% in 2020–2021, simultaneously with adoption of single rather than dual antiplatelet therapy in combination with DOAC. Conclusion: Between 2000 and 2021, among patients with MI and AF, we observed reductions in 1-year risks of ischaemic stroke or systemic embolism and CV mortality, occurring during a period of increased prescription of oral anticoagulants, particularly DOACs. Key question and findings: Key Question Have recent clinical trial findings on antithrombotic therapy in patients with myocardial infarction and concomitant atrial fibrillation been implemented, and have they resulted in any improvement in 1-year outcomes? Key Finding In patients with myocardial infarction and atrial fibrillation, we observed substantial reductions in 1-year risks of ischaemic stroke or systemic embolism and cardiovascular mortality, associated with increased prescribing of oral anticoagulants, particularly DOACs.


  • Open Access

    Association between quality of care indicators and clinical outcomes in patients undergoing transcatheter aortic valve implantation: insights from SWEDEHEART

    by Konrad Nilsson, Stefan James, Jenny Backes, Matthias Götberg, Henrik Hagström, Gorav Batra

    Aims: The European Society of Cardiology (ESC) has developed quality indicators (QIs) specifically for evaluating the care and outcomes for patients undergoing transcatheter aortic valve implantation (TAVI). The aim of this study was to evaluate TAVI care in all patients undergoing such procedures in Sweden using the ESC 2023 QIs for TAVI. Methods and results: We used the Swedish Transcatheter Cardiac Intervention Registry to identify all TAVI procedures performed in Swedish centres (n = 8) between 2008 and 2021. 8524 patients (median 82 years, 52.8% male) were included. In total, 24 (88.8%) of the 27 QIs could be captured from the available registry data. The attainment levels were generally high [median 97.8%, interquartile range (IQR) 91.3–100%] with small variations in attainment levels between centres. The greatest variations were observed in the QIs related to patients undergoing TAVI through transfemoral route (median 90.3%, IQR 85.6–96.9%), and in the proportion undergoing transfemoral TAVI without general anaesthesia (median 87.6%, IQR 57.1–94.4%). In total, 80% of the QIs were associated with 1-year all-cause mortality, and 85% with 1-year cardiovascular mortality. The QIs with greatest impact on 1-year mortality were the absence of coronary obstruction (adjusted HR 0.12; 95% CI 0.07–0.22), in-hospital stroke (adjusted HR 0.25; 95% CI 0.18–0.33) and no new dialysis (adjusted HR 0.25; 95% CI 0.15–0.41). Conclusion: In this study, the majority of the QIs were associated with both all-cause and cardiovascular mortality. Hence, the ESC 2023 QIs for TAVI may serve as a valuable tool for evaluating TAVI care, benchmarking performance, and improving patient outcomes.


  • Open Access

    Anticoagulation and antiplatelet strategies used in Sweden in patients with myocardial infarction and concomitant atrial fibrillation: nationwide cohort study

    by Julia Aulin, Angelo Modica, Lars Lindhagen, Joakim Alfredsson, Claes Held, Stefan James, Gorav Batra

    Background: Optimal antithrombotic therapy and its duration, whether triple therapy with dual antiplatelets plus oral anticoagulant (OAC), or dual antithrombotic therapy with an antiplatelet plus OAC, is uncertain for patients with myocardial infarction (MI) and atrial fibrillation (AF). Methods: Patients registered in SWEDEHEART (Swedish Web-system for enhancement and development of evidence-based care in heart disease evaluated according to recommended therapies) for their first MI between 2011 and 2021 with a history or new-onset AF were included (n=26 574). Linkage between SWEDEHEART and Swedish administrative health databases was performed, and pseudonymised data analysed. Results: Over time, OAC use at discharge after MI tripled from 27% in 2011 to 77% in 2021, with direct OACs (DOACs) largely replacing warfarin, predominantly in combination with a single antiplatelet. The strongest factors for initiating OAC therapy were the performance of coronary angiography (OR 1.53 (1.40–1.68)), and percutaneous coronary intervention (OR 1.49 (1.39–1.61)). However, the year of the MI was the most predictive variable associated with OAC initiation, with an OR of 9.31 (7.92–10.95) in 2021 compared with 2011. The clinical factors associated with lower likelihood of OAC initiation were dementia, liver disease, cancer and ST-elevation MI (STEMI) versus non-STEMI. Conclusions: Use of OAC has increased over the years in patients with MI and concurrent AF, primarily driven by the increased adoption of DOACs. Additionally, there has been a shift in antithrombotic combinations, with most patients in recent years receiving DOAC in combination with a single antiplatelet, reflecting the nationwide implementation of recent evidence and guidelines. However, significant variation in antithrombotic therapy strategies remains.


  • Outcome measures for randomised clinical trials and multicentre observational studies of cardiovascular diseases published in major clinical journals: systematic review and evidence mapping

    by Asad Bhatty, Chris Wilkinson, Suleman Aktaa, Gorav Batra, Benjamin Beska, Phyo H H Khaing, Ali Wahab, Keerthenan Raveendra, Ahmed Taha, Ramesh Nadarajah, et al.

    Background: Outcome measure choice and definition can determine the result of the study. We describe outcome measures and their definitions for cardiovascular studies in highly cited medical journals. Methods: Cardiovascular phase III or IV randomised clinical trials (RCTs) or multicentre observational studies published in the New England Journal of Medicine , Lancet or Journal of the American Medical Association between 1 January 2013 and 6 June 2024 from Embase and Ovid Medline were included. Two independent reviewers selected the studies and extracted the primary and secondary outcome measures from each publication. Results: 386 studies (83% RCTs; 17% observational) representing 10 699 147 participants were included. Studies investigated coronary heart disease (51%), cardiomyopathy/heart failure (22%), heart rhythm disease (15%), valvular heart disease (11%) and ‘other’ cardiovascular diseases (1%), with 45% investigating a device and 48% funded by industry. The most frequently reported primary outcome measure was a composite (63%), the most frequent component of which was myocardial infarction (58%). The use of a composite for the primary outcome measure increased from 49% of studies in 2013 to a peak of 85% in 2018. From 2013 to 2023, the median number of secondary outcome measures per study increased for RCTs (3–8) and observational studies (0–7). Definitions for cardiovascular mortality, myocardial infarction and stroke varied across the studies. Conclusions: For cardiovascular studies published in highly cited journals, there has been an expansion in the use of primary composite outcome measures and secondary outcome measures, with heterogeneity in the definition of primary outcome measures. A standardised approach to the use of cardiovascular outcomes measures is required.


  • Open Access

    Definitions of clinical study outcome measures for cardiovascular diseases: the European Unified Registries for Heart Care Evaluation and Randomized Trials (EuroHeart)

    by Chris Wilkinson, Asad Bhatty, Gorav Batra, Suleman Aktaa, Adam B. Smith, Jeremy Dwight, Marcin Rucinski, Sam Chappell, Joakim Alfredsson, David Erlinge, et al.

    Background and Aims Standardized definitions for outcome measures in randomized clinical trials and observational studies are essential for robust and valid evaluation of medical products, interventions, care, and outcomes. The European Unified Registries for Heart Care Evaluation and Randomised Trials (EuroHeart) project of the European Society of Cardiology aimed to create international data standards for cardiovascular clinical study outcome measures.Methods The EuroHeart methods for data standard development were used. From a Global Cardiovascular Outcomes Consortium of 82 experts, five Working Groups were formed to identify and define key outcome measures for: cardiovascular disease (generic outcomes), acute coronary syndrome and percutaneous coronary intervention (ACS/PCI), atrial fibrillation (AF), heart failure (HF) and transcatheter aortic valve implantation (TAVI). A systematic review of the literature informed a modified Delphi method to reach consensus on a final set of variables. For each variable, the Working Group provided a definition and categorized the variable as mandatory (Level 1) or optional (Level 2) based on its clinical importance and feasibility.Results Across the five domains, 24 Level 1 (generic: 5, ACS/PCI: 8, AF: 2; HF: 5, TAVI: 4) and 48 Level 2 (generic: 18, ACS-PCI: 7, AF: 6, HF: 2, TAVI: 15) outcome measures were defined.Conclusions Internationally derived and endorsed definitions for outcome measures for a range of common cardiovascular diseases and interventions are presented. These may be used for data alignment to enable high-quality observational and randomized clinical research, audit, and quality improvement for patient benefit.


  • Open Access

    Standardized and hierarchically classified heart failure and complementary disease monitoring outcome measures: European Unified Registries for Heart Care Evaluation and Randomised Trials (EuroHeart)

    by Asad Bhatty, Chris Wilkinson, Gorav Batra, Suleman Aktaa, Adam B Smith, Ali Wahab, Sam Chappell, Joakim Alfredsson, David Erlinge, Jorge Ferreira, et al.

    Aims: The lack of standardized definitions for heart failure outcome measures limits the ability to reliably assess the effectiveness of heart failure therapies. The European Unified Registries for Heart Care Evaluation and Randomised Trials (EuroHeart) aimed to produce a catalogue of internationally endorsed data definitions for heart failure outcome measures. Methods and results: Following the EuroHeart methods for the development of cardiovascular data standards, a working group was formed of representatives from the European Society of Cardiology Heart Failure Association and other leading heart failure experts. A systematic review of observational and randomized clinical trials identified current outcome measures, which was supplemented by clinical practice guidelines and existing registries for contemporary definitions. A modified Delphi process was employed to gain consensus for variable inclusion and whether collection should be mandatory (Level 1) or optional (Level 2) within EuroHeart. In addition, a set of complementary outcome measures were identified by the working group as of scientific and clinical importance for longitudinal monitoring for people with heart failure. Five Level 1 and two Level 2 outcome measures were selected and defined, alongside five complementary monitoring outcomes for patients with heart failure. Conclusion: We present a structured, hierarchical catalogue of internationally endorsed heart failure outcome measures. This will facilitate quality improvement, high quality observational research, registry-based trials, and post-market surveillance of medical devices.


  • Associations between psychosocial burden and prognostic biomarkers in patients with chronic coronary syndrome: a STABILITY substudy

    by Charlotte Wassberg, Gorav Batra, Nermin Hadziosmanovic, Emil Hagström, Harvey D White, Ralph A H Stewart, Agneta Siegbahn, Lars Wallentin, Claes Held

    Aims: To investigate associations between psychosocial (PS) burden and biomarkers reflecting pathophysiological pathways in patients with chronic coronary syndrome. Methods and results: Psychosocial factors were collected from self-assessed questionnaires and biomarkers representing inflammation [high-sensitivity (hs)-C-reactive protein (CRP), interleukin-6 (IL-6), lipoprotein-associated phospholipase A2 (Lp-PLA2)] and cardiac injury/stress [hs-troponin T (hs-TnT), N-terminal pro-B-type natriuretic peptide (NT-proBNP)] were measured in 12 492 patients with chronic coronary syndrome in the STABILITY trial. Associations between level of each PS factor [never–rarely (reference), sometimes, often–always] and biomarkers were evaluated using linear models with adjusted geometric mean ratios (GMR). A score comprising four factors (‘feeling down’, ‘loss of interest’, financial stress’, and ‘living alone’) that previously demonstrated association with cardiovascular (CV) outcome was created, and categorized into three levels: low, moderate, and high PS burden. Associations between PS score and biomarkers were evaluated similarly. Greater PS burden was significantly associated with a gradual increase in inflammatory biomarkers [GMR (95% confidence interval) for moderate vs. low PS burden; and high vs. low PS burden]: hs-CRP [1.09 (1.04–1.14); 1.12 (1.06–1.17)], IL-6 [1.05 (1.02–1.07); 1.08 (1.05–1.11)], LpPLA2 [1.01 (1.00–1.02); 1.02 (1.01–1.04)], and cardiac biomarkers hs-TnT [1.03 (1.01–1.06); 1.06 (1.03–1.09)] and NT-proBNP [1.09 (1.04–1.13); 1.21 (1.15–1.27)]. Conclusion: In patients with chronic coronary syndrome, greater PS burden was associated with increased levels of inflammatory and cardiac biomarkers. While this observational study does not establish causal nature of these associations, the findings suggest inflammation and cardiac injury/stress as plausible pathways linking PS burden to an elevated CV risk that needs to be further explored.


  • Open Access

    Major cardiovascular events and death in parents of children with type 1 diabetes: a register-based matched cohort study in Sweden

    by Beatrice Kennedy, Mona-Lisa Wernroth, Gorav Batra, Ulf Hammar, Cecilia Linroth, Annika Grönberg, Liisa Byberg, Tove Fall

    Aims/hypothesis: Parenting a child with type 1 diabetes has been associated with stress-related symptoms. This study aimed to elucidate the potential impact on parental risk of major cardiovascular events (MCE) and death. Methods: In this register-based study, we included the parents of 18,871 children, born 1987–2020 and diagnosed with type 1 diabetes in Sweden at <18 years. The median parental age at the child's diagnosis was 39.0 and 41.0 years for mothers and fathers, respectively. The cohort also encompassed 714,970 population-based matched parental control participants and 12,497 parental siblings. Cox proportional hazard regression models were employed to investigate the associations between having a child with type 1 diabetes and incident MCE and all-cause death, and, as secondary outcomes, acute coronary syndrome and ischaemic heart disease (IHD). We adjusted for potential confounders including parental type 1 diabetes and country of birth. Results: During follow-up (median 12 years, range 0–35), we detected no associations between parenting a child with type 1 diabetes and MCE in mothers (adjusted HR [aHR] 1.02; 95% CI 0.90, 1.15) or in fathers (aHR 1.01; 95% CI 0.94, 1.08). We noted an increased hazard of IHD in exposed mothers (aHR 1.21; 95% CI 1.05, 1.41) with no corresponding signal in fathers (aHR 0.97; 95% CI 0.89, 1.05). Parental sibling analysis did not confirm the association in exposed mothers (aHR 1.01; 95% CI 0.73, 1.41). We further observed a slightly increased hazard of all-cause death in exposed fathers (aHR 1.09; 95% CI 1.01, 1.18), with a similar but non-significant estimate noted in exposed mothers (aHR 1.07; 95% CI 0.96, 1.20). The estimates from the sibling analyses of all-cause death in fathers and mothers were 1.12 (95% CI 0.90, 1.38) and 0.73 (95% CI 0.55, 0.96), respectively. Conclusions/interpretation: Having a child diagnosed with type 1 diabetes in Sweden was not associated with MCE, but possibly with all-cause mortality. Further studies are needed to disentangle potential underlying mechanisms, and to investigate parental health outcomes across the full lifespan. Graphical


  • Cohort profile: the European Unified Registries On Heart Care Evaluation and Randomized Trials (EuroHeart)—acute coronary syndrome and percutaneous coronary intervention

    by Asad Bhatty, Chris Wilkinson, Gorav Batra, Joakim Alfredsson, David Erlinge, Jorge Ferreira, Ingibjörg J Guðmundsdóttir, Þórdís Jóna Hrafnkelsdóttir, Inga Jóna Ingimarsdóttir, Alar Irs, et al.

    The European Unified Registries On Heart care Evaluation And Randomized Trials (EuroHeart) aims to improve the quality of care and clinical outcomes for patients with cardiovascular disease. The collaboration of acute coronary syndrome/percutaneous coronary intervention (ACS/PCI) registries is operational in seven vanguard European Society of Cardiology member countries. Adults admitted to hospitals with ST-elevation myocardial infarction (STEMI) and non-ST-elevation myocardial infarction (NSTEMI) are included, and individual patient-level data collected and aligned according to the internationally agreed EuroHeart data standards for ACS/PCI. The registries provide up to 155 variables spanning patient demographics and clinical characteristics, in-hospital care, in-hospital outcomes, and discharge medications. After performing statistical analyses on patient data, participating countries transfer aggregated data to EuroHeart for international reporting. Between 1st January 2022 and 31st December 2022, 40 021 admissions (STEMI 46.7%, NSTEMI 53.3%) were recorded from 192 hospitals in the seven vanguard countries: Estonia, Hungary, Iceland, Portugal, Romania, Singapore, and Sweden. The mean age for the cohort was 67.9 (standard deviation 12.6) years, and it included 12 628 (31.6%) women. The EuroHeart collaboration of ACS/PCI registries prospectively collects and analyses individual data for ACS and PCI at a national level, after which aggregated results are transferred to the EuroHeart Data Science Centre. The collaboration will expand to other countries and provide continuous insights into the provision of clinical care and outcomes for patients with ACS and undergoing PCI. It will serve as a unique international platform for quality improvement, observational research, and registry-based clinical trials.